Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Lumify eye drops, the first OTC brimonidine tartrate ophthalmic solution 0.025% in the US, will reach stores in late May. Corporate name change, says CEO Joseph Papa, shows Valeant is "beginning to turn the page away from legacy issues that have been headwinds over the past few years."
You may also be interested in...
Bausch + Lomb Spreads Into US Cosmetics Market, Extends Lumify Brand With Eye Illuminations Line
Canadian firm launches US sales of Lumify Eye Illuminations 3-in-1 Micellar Cleansing Water and Eye Makeup Remover, Nourishing Lash & Brow Serum and Hydra-Gel Brightening Eye Cream. Each product contains hyaluronic acid, a fluid in eyes and joints which acts as a cushion and lubricant.
Lumify Reaches Canada As Consumer Health Leads Sales In Bausch + Lomb's Debut Quarter
Lumify sales grew reported 21% to brand-record $35m in Q2, Bausch + Lomb’s first quarter since separating from Bausch Health through an IPO in May.
Bausch + Lomb CEO Leaving 10 Weeks Following IPO, Month After Icahn Gains Two Board Seats
Joseph Papa steps down as chair and will remain at helm and on board until successor appointed. Guggenheim analysts reported representatives on B+L board for activist investor Carl Icahn appointed a month ago likely led to Papa’s exit.